Brachytherapy's use in prostate Ca is on the rise

"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

"In general, risk is related to return: the higher the risk, the higher the potential return; the lower the risk, the lower the potential return," writes Jeff Witz, CFP.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

"So, there's a lot of evidence to point to the androgen receptor being an important player in at least developing this disease," says Edward M. Messing, MD.

“Our results demonstrated that treatment with [the] Optilume BPH procedure resulted in significant symptom relief while still preserving erectile and ejaculatory function,” said Olivia Copelan, MD.